Results 81 to 90 of about 2,148,975 (183)
Example 1 - NOS - Há mais em nós (anúncio)
, 2023 NOS - Há mais em nós (anúncio)In the last 10 seconds of this advertisement NOS sound logo was revealed for the first time.Original Link - https://www.youtube.com/watch?v=ZkBsbg332AU"Dia 16 de Maio, nasceu uma nova marca.Encontra-nos em www.nos.pt e em ...
NOS SGPS S.A. (17116910)
core +1 more source
iLABMED, Volume 4, Issue 2, Page 91-107, June 2026.This article reviews the pivotal role of post‐translational modifications of proteins in the development and progression of hematologic malignancies, and explores their clinical translation potential as novel biomarkers and therapeutic targets. ABSTRACT Post‐translational modifications (PTMs) of proteins have emerged as critical regulators in the ...
Yuxuan Han +6 more
wiley +1 more source
Example 7 - NOS - Cante Alentejano Património Imaterial da Humanidade.
, 2023 NOS Cante Alentejano Campaign - "NOS - Cante Alentejano Património Imaterial da Humanidade."Original Link: https://www.youtube.com/watch?v=K4dX_DGVjm427/11 ...
NOS SGPS S.A. (17116910)
core +1 more source
PIM kinases as potential therapeutic targets in PTCL.
, 2014 (A) Gene expression profiling of tumoral samples from 38 human PTCL patients compared with 6 reactive lymph nodes (LN) by microarrays revealed a significantly increased expression of PIM1 and PIM2 genes ...
Carmen Almaraz (215288) +23 more
core +1 more source
Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation
MedComm – Oncology, Volume 5, Issue 2, June 2026.The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong +4 more
wiley +1 more source
Lack of SMARCB1 expression characterizes a subset of human and murine peripheral T-cell lymphomas
Nature CommunicationsPeripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of malignancies with poor outcome. Here, we identify a subgroup, PTCL-NOS SMARCB1- , which is characterized by the lack of the SMARCB1 protein and occurs more ...
Anja Fischer +54 more
doaj +1 more source
Tv and radio survey ( NOS ) by telephone 1976-1977
, 2007 Various issues about tv programs, radio programs perspectives, expectations. Background variables: basic characteristics/ residence/ household characteristics/ education/ politics/ consumption of durables/ readership, mass media, and 'cultural' exposure/
Nederlandse omroep stichting, NOS * Hilversum, Afd. kijk- en luisteronderzoek (primary investigator)
core +1 more source
, 2015 Background: Peripheral T-cell lymphomas (PTCL) have an aggressive clinical course with a poor 5-year overall survival with conventional therapy. Autologous stem cell transplantation (autoSCT) and allogeneic stem cell transplantation (alloSCT) can improve
Francesco Maura +14 more
core
Gene expression is deregulated in Dnmt3aΔ/Δ PTCL.
, 2016 (A) Heat map of RNA-seq global expression data displaying differentially expressed genes in Dnmt3a+/- and Dnmt3aΔ/Δ PTCL (≥2 fold change and a p-value wild-type CD8+ cells, 737 genes were overexpressed and 697 genes were underexpressed in both Dnmt3a ...
Sohini Roy (743212) +8 more
core +1 more source
Autopsy and Case Reports, 2022 Peripheral neuropathy (PN) is characterized by the injury to the peripheral nervous system of varied etiology. Lymphoma is one of the etiologies of PN, presenting various neurological manifestations. Neuropathy associated with peripheral T-cell lymphoma,
Ratul Seal +3 more
doaj